Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 422

1.

Reduced colonization and infection with miconazole-rifampicin modified central venous catheters: a randomized controlled clinical trial.

Yücel N, Lefering R, Maegele M, Max M, Rossaint R, Koch A, Schwarz R, Korenkov M, Beuth J, Bach A, Schierholz J, Pulverer G, Neugebauer EA.

J Antimicrob Chemother. 2004 Dec;54(6):1109-15. Epub 2004 Nov 10.

PMID:
15537696
2.

[Special aspects of implant-associated infection in orthopedic surgery. From the pathophysiology to custom-tailored prevention strategies].

Schierholz JM, Morsczeck C, Brenner N, König DP, Yücel N, Korenkov M, Neugebauer E, Rump AF, Waalenkamp G, Beuth J, Pulverer G, Arens S.

Orthopade. 2004 Apr;33(4):397-404. Review. German.

PMID:
15141663
3.

Human cervicofacial actinomycoses: microbiological data for 1997 cases.

Pulverer G, Schütt-Gerowitt H, Schaal KP.

Clin Infect Dis. 2003 Aug 15;37(4):490-7. Epub 2003 Jul 30.

PMID:
12905132
4.

Antiinfective and encrustation-inhibiting materials--myth and facts.

Schierholz JM, Yücel N, Rump AF, Beuth J, Pulverer G.

Int J Antimicrob Agents. 2002 Jun;19(6):511-6.

PMID:
12135842
5.

Novel strategies to prevent catheter-associated infections in oncology patients.

Schierholz JM, Beuth J, Rump A, König DP, Pulverer G.

J Chemother. 2001 Nov;13 Spec No 1(1):239-50. Review.

PMID:
11936373
6.

[Prevention of infection with Streptococcus pneumoniae].

Randerath O, König D, Saalmann M, Jansen B, Pulverer G.

Med Klin (Munich). 2000 Dec 15;95(12):678-82. German.

PMID:
11198555
7.

The antimicrobial efficacy of a new central venous catheter with long-term broad-spectrum activity.

Schierholz JM, Fleck C, Beuth J, Pulverer G.

J Antimicrob Chemother. 2000 Jul;46(1):45-50.

PMID:
10882687
8.

"Difficult to treat infections" pharmacokinetic and pharmacodynamic factors--a review.

Schierholz JM, Beuth J, Pulverer G.

Acta Microbiol Immunol Hung. 2000;47(1):1-8. Review.

PMID:
10735184
9.

Evidence for a self-fulfilling hypothesis: chlorhexidine dressing for reduction of microbial colonization of the skin with central venous catheters.

Schierholz JM, Beuth J, Pulverer G.

J Hosp Infect. 2000 Mar;44(3):241-3. No abstract available.

PMID:
10706809
10.
11.

Central venous catheters and bloodstream infection.

Schierholz J, Lefering R, Neugebauer E, Beuth J, König DP, Pulverer G.

JAMA. 2000 Jan 26;283(4):477-8; author reply 478-9. No abstract available.

PMID:
10659869
12.

Silver-containing polymers.

Schierholz JM, Beuth J, Pulverer G, König DP.

Antimicrob Agents Chemother. 1999 Nov;43(11):2819-20; author reply 2820-1. No abstract available.

13.

The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection.

Schierholz JM, Beuth J, Pulverer G, König DP.

Am J Med. 1999 Nov;107(5):534-5. No abstract available.

PMID:
10569319
14.

In vitro activity of rifampin-minocyclin coating to Candida albicans.

Schierholz JM, Pulverer G, Bach A, Wachol-Drebeck Z.

Crit Care Med. 1999 Aug;27(8):1691-3. No abstract available.

PMID:
10470803
15.

Silver coating of medical devices for catheter-associated infections?

Schierholz JM, Beuth J, Pulverer G.

Am J Med. 1999 Jul;107(1):101-2. No abstract available.

PMID:
10403360
16.

The quantity and duration of the antimicrobial efficacy of a chlorhexidine and silversulfadiazine impregnated catheter.

Schierholz JM, Beuth J, Pulverer G.

J Hosp Infect. 1999 Jun;42(2):163-5. No abstract available.

PMID:
10389069
17.

The myth of encrustation inhibiting materials.

Schierholz JM, König DP, Beuth J, Pulverer G.

J Hosp Infect. 1999 Jun;42(2):162-3. No abstract available.

PMID:
10389068
18.

Adherent bacteria and activity of antibiotics.

Schierholz JM, Beuth J, Pulverer G.

J Antimicrob Chemother. 1999 Jan;43(1):158-60. No abstract available.

PMID:
10381118
19.

Antimicrobial substances and effects on sessile bacteria.

Schierholz JM, Beuth J, König D, Nürnberger A, Pulverer G.

Zentralbl Bakteriol. 1999 Apr;289(2):165-77. Review.

PMID:
10360317
20.

Killing effects of antibiotics and two-fold antimicrobial combinations on proliferating and non growing staphylococci.

Schierholz JM, Beuth J, Pulverer G.

Zentralbl Bakteriol. 1998 Dec;288(4):527-39.

PMID:
9987191
21.

Investigation of a rifampin, fusidic-acid and mupirocin releasing silicone catheter.

Schierholz JM, Pulverer G.

Biomaterials. 1998 Nov;19(22):2065-74.

PMID:
9870758
22.

Efficacy of silver-coated medical devices.

Schierholz JM, Lucas LJ, Rump A, Pulverer G.

J Hosp Infect. 1998 Dec;40(4):257-62. Review.

PMID:
9868616
23.

Anti-infective catheters: novel strategies to prevent nosocomial infections in oncology.

Schierholz JM, Rump AF, Pulverer G, Beuth J.

Anticancer Res. 1998 Sep-Oct;18(5B):3629-38.

PMID:
9854469
24.

Actinobacillus actinomycetemcomitans in the human oral microflora.

Pulverer G, Schütt-Gerowitt H.

Zentralbl Bakteriol. 1998 Jul;288(1):87-92.

PMID:
9728408
25.

Adjuvant properties of killed Propionibacterium avidum KP-40 in vaccination of dogs against canine parvovirosis.

Siwicki AK, Krzyzanowski J, Bartoszcze M, Mizak Z, Paluch S, Szmigielski S, Jeljaszewicz J, Pulverer G.

Dtsch Tierarztl Wochenschr. 1998 May;105(5):186-90.

PMID:
9646552
26.

Activity of silver ions in different media.

Schierholz JM, Wachol-Drewek Z, Lucas LJ, Pulverer G.

Zentralbl Bakteriol. 1998 May;287(4):411-20.

PMID:
9638870
27.
28.

Development of a new CSF-shunt with sustained release of an antimicrobial broad-spectrum combination.

Schierholz JM, Pulverer G.

Zentralbl Bakteriol. 1997 Jun;286(1):107-23.

PMID:
9241806
29.

Controlled release of antibiotics from biomedical polyurethanes: morphological and structural features.

Schierholz JM, Steinhauser H, Rump AF, Berkels R, Pulverer G.

Biomaterials. 1997 Jun;18(12):839-44.

PMID:
9184747
30.

[Clinical and preclinical efficacy of antimicrobial catheters].

Schierholz JM, Rump AF, Pulverer G.

Anasthesiol Intensivmed Notfallmed Schmerzther. 1997 May;32(5):298-305. Review. German.

PMID:
9264617
31.

Prevention of hepatic metastases by liver lectin blocking with D-galactose in stomach cancer patients. A prospectively randomized clinical trial.

Kosik J, Gil J, Szmigielski S, Beuth J, Pulverer G.

Anticancer Res. 1997 Mar-Apr;17(2B):1411-5.

PMID:
9137507
32.

Prevention of hepatic metastases by liver lectin blocking with D-galactose in colon cancer patients. A prospectively randomized clinical trial.

Warczynski P, Gil J, Szmigielski S, Beuth J, Pulverer G.

Anticancer Res. 1997 Mar-Apr;17(2B):1223-6.

PMID:
9137476
33.

Protection and therapy of experimental herpesvirus infections in mice with immunomodulating Propionibacterium avidum KP-40 and/or acyclovir.

Kobus M, Luczak M, Sobiczewska E, Szmigielski S, Jeljaszewicz J, Pulverer G.

Zentralbl Bakteriol. 1997 Feb;285(3):445-9.

PMID:
9084118
34.
35.

Microflora-associated defense stimulating factors.

Pulverer G, Lioe Ko H, Beuth J.

Scand J Gastroenterol Suppl. 1997;222:107-11. doi: 10.1080/00365521.1997.11720732. Review.

PMID:
9145461
36.
37.

Effect of immunomodulation with galactoside-specific mistletoe lectin on experimental listeriosis.

Stoffel B, Beuth J, Pulverer G.

Zentralbl Bakteriol. 1996 Jul;284(2-3):439-42.

PMID:
8837402
38.

Drug delivery concepts for the efficacious prevention of foreign-body infections.

Schierholz JM, Rump A, Pulverer G.

Zentralbl Bakteriol. 1996 Jul;284(2-3):390-401.

PMID:
8837400
39.

Adhesive properties of P-like fimbriae in Klebsiella-species.

Przondo-Mordarska A, Smutnicka D, Ko HL, Beuth J, Pulverer G.

Zentralbl Bakteriol. 1996 Jul;284(2-3):372-7.

PMID:
8837398
40.

Influence of Propionibacterium avidum KP-40 on the cellular immune system after intensive sport activity.

Pottkämper M, Randerath O, Beuth J, Pulverer G.

Zentralbl Bakteriol. 1996 Jul;284(2-3):367-71.

PMID:
8837397
41.

Serum antibody reactivity to recombinant mig and whole cell antigens in Mycobacterium avium infection.

Plum G, Brenden M, Santos P, Schwarz E, Wahnschaffe U, Mauff G, Pulverer G.

Zentralbl Bakteriol. 1996 Jul;284(2-3):348-60.

PMID:
8837395
42.
43.

Campylobacter and Salmonella contaminating fresh chicken meat.

Geilhausen B, Schütt-Gerowitt H, Aleksic S, Koenen R, Mauff G, Pulverer G.

Zentralbl Bakteriol. 1996 Jul;284(2-3):241-5.

PMID:
8837384
44.

Problems and priorities for controlling opportunistic pathogens with new antimicrobial strategies; an overview of current literature.

Araneo BA, Cebra JJ, Beuth J, Fuller R, Heidt PJ, Midvedt T, Nord CE, Nieuwenhuis P, Manson WL, Pulverer G, Rusch VC, Tanaka R, van der Waaij D, Walker RI, Wells CL.

Zentralbl Bakteriol. 1996 Apr;283(4):431-65. Review.

PMID:
8737943
45.

A four-year prospective study on microbial ecology of explanted prosthetic hips in 52 patients with "aseptic" prosthetic joint loosening.

Perdreau-Remington F, Stefanik D, Peters G, Ludwig C, Rütt J, Wenzel R, Pulverer G.

Eur J Clin Microbiol Infect Dis. 1996 Feb;15(2):160-5.

PMID:
8801090
46.

Modulating activity of mistletoe lectins 1 and 2 on the lymphatic system in BALB/c-mice.

Beuth J, Stoffel B, Samtleben R, Staak O, Ko HL, Pulverer G, Wagner H.

Phytomedicine. 1996 Jan;2(3):269-73. doi: 10.1016/S0944-7113(96)80054-7.

PMID:
23194628
47.

Inhibition of bacterial adhesion and infections by lectin blocking.

Beuth J, Stoffel B, Pulverer G.

Adv Exp Med Biol. 1996;408:51-6. Review. No abstract available.

PMID:
8895776
48.

Respiratory burst of human polymorphonuclear leukocytes in response to the galactoside-specific mistletoe lectin.

Braun JM, Gemmell CG, Beuth J, Ko HL, Pulverer G.

Zentralbl Bakteriol. 1995 Nov;283(1):90-4.

PMID:
9810649
49.

Immunomodulating ability of galactoside-specific lectin standardized and depleted mistletoe extract.

Beuth J, Stoffel B, Ko HL, Jeljaszewicz J, Pulverer G.

Arzneimittelforschung. 1995 Nov;45(11):1240-2.

PMID:
8929248
50.

In-vitro activity of a catheter loaded with silver and teicoplanin to prevent bacterial and fungal colonization.

Jansen B, Ruiten D, Pulverer G.

J Hosp Infect. 1995 Nov;31(3):238-41. No abstract available.

PMID:
8586795

Supplemental Content

Loading ...
Support Center